Finch Therapeutics Group Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Matt Blischak

Algemeen directeur

US$775.7k

Totale compensatie

Percentage CEO-salaris	32.5%
Dienstverband CEO	1.5yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	1.5yrs
Gemiddelde ambtstermijn bestuur	6.2yrs

Recente managementupdates

Recent updates

Finch to cut workforce by about 37% after Takeda ends bowel disease collaboration

Sep 01

Finch to get back rights to IBD product candidates after Takeda ends collaboration

Aug 25

Finch Therapeutics GAAP EPS of -$0.48 misses by $0.07, revenue of $0.36M

Aug 11

Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation

Mar 15

Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation

Dec 15

We Think Finch Therapeutics Group (NASDAQ:FNCH) Needs To Drive Business Growth Carefully

Aug 28

Finch Therapeutics: Gut Instinct Says Buy

Jun 14

Analyse CEO-vergoeding

Hoe is Matt Blischak's beloning veranderd ten opzichte van Finch Therapeutics Group's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$14m
Mar 31 2024	n/a	n/a	-US$16m
Dec 31 2023	US$776k	US$252k	-US$75m

Compensatie versus markt: De totale vergoeding ($USD 775.65K ) Matt } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 655.02K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Matt te vergelijken met de prestaties van het bedrijf.

CEO

Matt Blischak (61 yo)

1.5yrs

Tenure

US$775,651

Compensatie

Mr. Matthew P. Blischak, also known as Matt, JD, serves as Chief Executive Officer of Finch Therapeutics Group, Inc. since May 16, 2023 and serves as its President & Secretary since May 2023. He has intell...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Matthew Blischak	President	1.5yrs	US$775.65k	geen gegevens
Lance Thibault	Chief Financial Officer	1.5yrs	US$168.79k	geen gegevens
James Sigler	Executive Vice President of CMC	6.8yrs	geen gegevens	geen gegevens

1.5yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van FNCH wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.5 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jeffery Smisek	Independent Director	7.8yrs	US$2.29k	2.63% $ 513.4k
Chris Shumway	Independent Director	4.2yrs	US$2.29k	26.24% $ 5.1m
Christian Lange	Independent Chair	7.2yrs	US$2.29k	0% $ 0
Domenic Ferrante	Independent Director	5.2yrs	US$2.29k	1.32% $ 257.7k

6.2yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van FNCH wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.2 jaar).

Finch Therapeutics Group Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Finch Therapeutics Group, Inc. Announces Resignation of Joseph Vittiglio as Chief Business and Legal Officer and Secretary, Effective December 31, 2022

High number of new directors

Finch Therapeutics Group, Inc. Announces Executive Appointments

High number of new directors

Key Executive recently bought US$12m worth of stock

Recent updates

Finch Therapeutics to Delist Its Common Stock from the Nasdaq Global Select Market on or About October 31, 2024 and Announces SEC Deregistration

Finch Therapeutics Group, Inc.(OTCPK:FNCH) dropped from NASDAQ Composite Index

Finch Therapeutics Group Receives the Delisting Letter from the Office of the General Counsel of Nasdaq Notifying the Listing Panel Determines to Delist the Company from Nasdaq

Nasdaq Listing Qualifications Department Issues an Additional Staff Determination to Finch Therapeutics Group for Continued Non-Compliance with the Market Value of Publicly Held Shares Rule

Finch Therapeutics Receives Notice from Nasdaq Regarding Non-Compliance with the Requirements of Nasdaq Listing Rule 5605(c)(2)

The Nasdaq Stock Market LLC Notifies Finch Therapeutics Regarding Company’s Status as 'Public Shell'

Finch Therapeutics Group Receives Non-Compliance Notice from Nasdaq

New major risk - Share price stability

Finch Therapeutics Announces 1-for-30 Reverse Stock Split of Common Stock to Satisfy the Minimum Price Requirement for Continued Listing on the Nasdaq Global Select Market

First quarter 2023 earnings released: US$1.33 loss per share (vs US$0.52 loss in 1Q 2022)

Finch Therapeutics Group, Inc. Reports Unaudited Consolidated Impairment of Long-Lived Assets for the First Quarter Ended March 31, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Finch Therapeutics Group, Inc. Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets

Finch Therapeutics Group, Inc. Announces Resignation of Joseph Vittiglio as Chief Business and Legal Officer and Secretary, Effective December 31, 2022

Price target decreased to US$12.00

Finch Therapeutics Group, Inc. Plans to Reduce its Workforce by Approximately 37%

Finch to cut workforce by about 37% after Takeda ends bowel disease collaboration

Finch to get back rights to IBD product candidates after Takeda ends collaboration

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Finch Therapeutics GAAP EPS of -$0.48 misses by $0.07, revenue of $0.36M

High number of new directors

Finch Therapeutics Group, Inc.(NasdaqGS:FNCH) dropped from Russell 2500 Value Index

Finch Therapeutics Announces Workforce Restructuring to Focus Resources on Key Development Programs

Price target decreased to US$27.67

Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation

Finch Therapeutics Group, Inc. Pauses Enrollment in PRISM4 Its Phase 3 Clinical Trial of CP101 in Recurrent C. Difficile Infection

Finch Therapeutics Group, Inc. Announces Executive Appointments

Finch Therapeutics Group, Inc. Announces U.S. Patent and Trademark Office Grants Two New Patents for FIN-211

High number of new directors

Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation

Third quarter 2021 earnings released: US$0.21 loss per share

We Think Finch Therapeutics Group (NASDAQ:FNCH) Needs To Drive Business Growth Carefully

Finch Therapeutics: Gut Instinct Says Buy

Key Executive recently bought US$12m worth of stock

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd